A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy.,Scientific Reports

当前位置： X-MOL 学术 › Sci. Rep. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy.
Scientific Reports ( IF 3.8 ) Pub Date : 2020-01-28 , DOI: 10.1038/s41598-020-58346-3
Yan Gao ₁ , Yi Chong Kelvin Teo _{1,

2} , Roger W Beuerman _{1,

3,

4} , Tien Yin Wong _{1,

2,

3,

4} , Lei Zhou _{1,

3,

4} , Chui Ming Gemmy Cheung _{1,

2,

4}

Affiliation

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the current standard of treatment for choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD), but there are no diagnostic tools to predict response of these therapies. We hypothesize that differences in baseline metabolic profiles of patients with nAMD may influence responsiveness to anti-VEGF therapy, and thus provide prognosticating information for these patients. A prospective study was performed on 100 patients with nAMD treated with anti-VEGF therapy. We classified patients into two groups: responders (n = 54) and non-responders (n = 46). The expression levels of glycerophosphocholine,LysoPC (18:2) and PS (18:0/20:4) were higher in non-responders and these findings were verified in the validation cohort, implicating that reductions in these three metabolites can be used as predictors for responsiveness to anti-VEGF therapy during the initial loading phase for patients with nAMD. Our study also provided new insights into the pathophysiological changes and molecular mechanism of anti- VEGF therapy for nAMD patients.

中文翻译：

nAMD 患者抗 VEGF 治疗反应的血清代谢组学研究。

玻璃体内注射抗血管内皮生长因子（抗 VEGF）是继发于新生血管性年龄相关性黄斑变性（nAMD）的脉络膜新生血管（CNV）的当前治疗标准，但没有诊断工具可以预测这些疗法的反应。我们假设 nAMD 患者基线代谢特征的差异可能会影响抗 VEGF 治疗的反应，从而为这些患者提供预后信息。对 100 名接受抗 VEGF 治疗的 nAMD 患者进行了一项前瞻性研究。我们将患者分为两组：有反应者 (n = 54) 和无反应者 (n = 46)。无反应者中甘油磷酸胆碱、LysoPC (18:2) 和 PS (18:0/20:4) 的表达水平较高，这些发现在验证队列中得到了验证，这意味着这三种代谢物的减少可用作nAMD 患者初始负荷阶段对抗 VEGF 治疗反应的预测因子。我们的研究还为nAMD患者的病理生理变化和抗VEGF治疗的分子机制提供了新的见解。

更新日期：2020-01-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南